Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
304 participants
INTERVENTIONAL
2012-12-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain
NCT01298765
Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain
NCT01431742
An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
NCT01666119
Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects
NCT01713803
Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain
NCT00490919
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EN3409
Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
EN3409
Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EN3409
Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male subjects who are practicing abstinence, surgically sterile, or are using a medically acceptable form of contraception
* De Novo subject with a clinical diagnosis of moderate to severe noncancer-related CP (eg, CLBP, OA, neuropathic pain) for ≥ 3 months
* De Novo subject that is treating their CP with a stable daily maintenance dose of ATC opioid analgesic medication equivalent to ≥ 60 mg and ≤ 160 mg Morphine Sulfate Equivalent (MSE) per day for ≥ 4 weeks
* Stable health, as determined by the Principal Investigator
* Subject is willing and able to comply with all protocol required visits and assessments
* Rollover subject who has completed the 12-week Double-blind Treatment Phase in the EN3409-307/308 clinical study
Exclusion Criteria
* Females who are pregnant, breastfeeding, or plan to become pregnant during the study
* Current cancer-related pain or received chemotherapy within 6 months of screening
* Subjects receiving opioid analgesic medication \< 60 mg MSE per day within 28 days of screening
* De novo subjects receiving opioid analgesic medication at doses of \> 160 mg MSE per day within 28 days of screening
* Subjects with a history of other chronic painful conditions, other than the index CP condition, which require frequent analgesic medication
* Reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis
* History of allergy or contraindications to any opioid or acetaminophen
* Surgical procedure for relief of pain within 6 months, or nerve/plexus block within 28 days of screening
* Hypokalemia or clinically unstable cardiac disease
* Moderate to severe hepatic impairment
* Moderate to severe renal impairment
* Current or past history of alcohol or substance
* Positive urine toxicology screen for drugs of abuse
* History of abnormalities on physical exam, vital signs, ECG, or lab values
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
BioDelivery Sciences International
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Finn, PharmD
Role: STUDY_DIRECTOR
BioDelivary Sciences Internantional, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parkway Medical Center
Birmingham, Alabama, United States
Horizon Research Group, Inc
Mobile, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
Global Research, LLC
Anaheim, California, United States
Synergy Clinical Research Center of Escondido
Escondido, California, United States
RX Clinical Research, Inc.
Garden Grove, California, United States
Long Beach Center for Clinical Research
Long Beach, California, United States
Adam D. Karns, MD
Los Angeles, California, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States
Century Clinical Research, Inc.
Daytona Beach, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
Florida Health Center
Fort Lauderdale, Florida, United States
Eastern Research, Inc.
Hialeah, Florida, United States
Southeast Clinical Research, LLC
Jacksonville, Florida, United States
Health Awareness, Inc.
Jupiter, Florida, United States
Research Centers of America, LLC
Oakland Park, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Ribo Research LLC DBA Peninsula Research
Ormond Beach, Florida, United States
Gold Coast Research, LLC
Plantation, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Clinical Research of West Florida, Inc.
Tampa, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
National Pain Research Institute, LLC
Winter Park, Florida, United States
River Birch Research Alliance, LLC
Blue Ridge, Georgia, United States
Drug Studies America
Marietta, Georgia, United States
Taylor Research, LLC
Marietta, Georgia, United States
In-Quest Medical Research, LLC
Norcross, Georgia, United States
Global Scientific Innovations
Evansville, Indiana, United States
Integrated Clinical Trials Services, Inc.
West Des Moines, Iowa, United States
Willis-Knighton Physician Network
Bossier City, Louisiana, United States
Clinical Trials Management, LLC
Metairie, Louisiana, United States
Best Clinical Trials, LLC
New Orleans, Louisiana, United States
River Cities Clinical Research Center
Shreveport, Louisiana, United States
New England Center for Clinical Research, Inc.
Fall River, Massachusetts, United States
Great Lakes Research Group, Inc.
Bay City, Michigan, United States
Cadillac Clinical Research
Cadillac, Michigan, United States
The Center for Clinical Trials
Biloxi, Mississippi, United States
Long Island Gastrointestinal Research Group
Great Neck, New York, United States
Upstate Clinical Research Associates
Williamsville, New York, United States
The Center for Clinical Research
Winston-Salem, North Carolina, United States
Plains Medical Clinic, LLC
Fargo, North Dakota, United States
Clinical Inquest Center, Ltd
Beavercreek, Ohio, United States
New Horizons Clinical Research
Cincinnati, Ohio, United States
Prestige Clinical Research
Franklin, Ohio, United States
Optimed Research, Ltd.
Tiffin, Ohio, United States
Brandywine Clinical Research
Downingtown, Pennsylvania, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Pain Specialists of Charleston, P.A.
Charleston, South Carolina, United States
Health Concepts
Rapid City, South Dakota, United States
FutureSearch Clinical Trials
Austin, Texas, United States
KRK Medical Research
Dallas, Texas, United States
FutureSearch Trials of Dallas, LP
Dallas, Texas, United States
Advanced Clinical Research of Houston
Houston, Texas, United States
Innovative Clinical Trials
San Antonio, Texas, United States
Highland Clinical Research
Salt Lake City, Utah, United States
Clinical Investigations Specialist, Inc.
Kenosha, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EN3409-309
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.